| Literature DB >> 6717902 |
O Kokron, S Maca, W Scheiner, M De Gregorio, G B Ciottoli.
Abstract
31 patients with inoperable non-small-cell lung cancer were treated with Lonidamine at daily doses of 450-900 mg orally. Side effects mostly consisted of myalgias, often severe, and gastrointestinal symptoms. Lonidamine was discontinued in 8 patients because of tumor progression and in 2 on account of side effects. 3 partial responses were observed, 2 in patients with epidermoid tumors.Entities:
Mesh：
Substances：
Year: 1984 PMID： 6717902 DOI： 10.1159/000225893
Source DB: PubMed Journal: Oncology ISSN： 0030-2414 Impact factor: 2.935